HER2-low is a new category defined by immunohistochemistry (IHC) as a score of 1+ or 2+ with a negative in situ hybridization (ISH) result (i.e., no HER2 gene amplification). Traditional HER2-targeted therapies (like trastuzumab) are only effective in HER2-positive (IHC 3+ or ISH+) cancers. However, the antibody-drug conjugate trastuzumab deruxtecan has shown efficacy in metastatic breast cancer with HER2-low expression. Accurate IHC testing is therefore critical to identify this patient population for potential treatment with this new class of drug.

Break down complex topics into smaller, manageable chunks for easier recall.

Zambia

• Joseph Soko – 101 pts

• Visual Pathway Lesions
• Positive and Negative Symptoms
• Hallucinations and Delusions
• Antipsychotic Medications
• Emergency: Environmental Emergencies